Sanofi to invite recruitment of phase III study for Accomplia TM.

Sanofi-Aventis will conduct clinical studies of "RIO-Asia" and "CRESCENDO" for the total 280 Korean obese patients for the assessment of 'Accomplia TM' (Rimonabant) a new anti-fat therapy especially against the abdominal fat.

Two clinical studies will be the first trial of conducting a large scale of multinational phase III clinical studies, and the company invites volunteer patients to test...